NextCure (NASDAQ:NXTC) Posts Earnings Results, Misses Expectations By $0.39 EPS

NextCure (NASDAQ:NXTC) announced its quarterly earnings data on Tuesday. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.39), FiscalAI reports.

NextCure Stock Performance

Shares of NXTC stock opened at $5.98 on Wednesday. The company has a market capitalization of $27.39 million, a P/E ratio of -0.69 and a beta of 1.22. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The stock has a 50 day moving average price of $6.05 and a two-hundred day moving average price of $7.63.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 5,626 shares of the business’s stock in a transaction dated Friday, October 23rd. The shares were purchased at an average price of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the acquisition, the insider owned 728,045 shares of the company’s stock, valued at approximately $3,516,457.35. This trade represents a 0.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have purchased a total of 15,537 shares of company stock valued at $77,603 in the last quarter. 11.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, NextCure has a consensus rating of “Hold” and a consensus price target of $20.00.

About NextCure

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.